Please login to the form below

Not currently logged in
Email:
Password:

Crohn's disease

This page shows the latest Crohn's disease news and features for those working in and with pharma, biotech and healthcare.

Homesick

Homesick

susceptible are those with underlying co-morbidities like metabolic syndrome and cardiovascular disease. ... And then we have a whole ‘other’ group – patients with psoriasis, rheumatoid arthritis, Crohn’s disease, and also oncology patients.

Latest news

  • AbbVie says Allergan takeover delayed by FTC verdict AbbVie says Allergan takeover delayed by FTC verdict

    position. There’s no specified timeline for that review to complete, but AbbVie says it has “entered into a timing agreement with FTC staff that would likely result” in a ... AZ licensed the drug – which is in late-stage testing for ulcerative

  • After FDA refusal, Takeda builds case for subcutaneous Entyvio After FDA refusal, Takeda builds case for subcutaneous Entyvio

    Intravenous Entyvio is already available in 60 countries. Takeda has reported updated results from a trial of its subcutaneous formulation of Entyvio in Crohn’s disease, showing activity over a year ... An enhanced clinical response rate – defined as

  • AbbVie lauds head-to-head win for Skyrizi versus Cosentyx AbbVie lauds head-to-head win for Skyrizi versus Cosentyx

    according to AbbVie outperformed its rival across all the trial’s primary and secondary outcome measures. ... It also has registration trials for Skyrizi ongoing in Crohn's disease and ulcerative colitis due to generate results next year, as well as

  • Takeda’s subcutaneous Entyvio formulation faces FDA rejection Takeda’s subcutaneous Entyvio formulation faces FDA rejection

    treatments. It also indicated for use in adult patients with moderate-to-severe active Crohn’s Disease who have similarly had inadequate responses to standard treatments. ... after a lead-in period, were in remission from the inflammatory bowel disease

  • PMEA 2019: Recognising excellence in improving patient outcomes PMEA 2019: Recognising excellence in improving patient outcomes

    Taking home this award was Takeda and Uptake Strategies for ENTYVIO’s Brand Healing (see image below), which positively impacted thousands of Ulcerative Colitis and Crohn’s Disease patients across the ... The two winners of this impressive award were

More from news
Approximately 20 fully matching, plus 152 partially matching documents found.

Latest Intelligence

  • Gut instincts lead Takeda to GI pipeline success Gut instincts lead Takeda to GI pipeline success

    with Crohn’s disease or ulcerative colitis is expected to rise by around 25% by 2025, according to recent studies. ... This will help physicians take much better care of patients for something that is a lifetime disease.”.

  • Case study: 4 Sites – Navigating the course ahead Case study: 4 Sites – Navigating the course ahead

    Client:SCITERION. Agency:N/A. Campaign:4 Sites: Navigating the course ahead. Timescale:N/A. Crohn’s disease – a chronic, debilitating and progressive disease – is on the increase worldwide, but remission

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    The first test of this will be Shire’s new blockbuster-in-waiting Takhzyro, which gained EMA approval in November, for the rare disease hereditary angioedema (HAE). ... Boehringer Ingelheim) for psoriatic arthritis, Crohn’s disease and other

  • Deal Watch October 2018

    Collaboration for. development. $760m. Enterome/. Takeda. EB8018 for Crohn’s disease and other gastrointestinal. ... Roche has an existing agreement with Ionis for IONIS‐HTTRx, an antisense drug for Huntington’s Disease, and the new deal is to

  • Innovation in merger control and the impact on the pharmaceutical sector Innovation in merger control and the impact on the pharmaceutical sector

    Pipeline problems. The Commission’s novel approach has its roots in pharma mergers. ... Specifically, Hospira was selling Inflectra, an infliximab biosimilar used to treat several chronic inflammatory diseases, notably the inflammation of Crohn’s

More from intelligence
Approximately 0 fully matching, plus 24 partially matching documents found.

Latest appointments

  • TiGenix appoints Dr Marie Paule Richard TiGenix appoints Dr Marie Paule Richard

    in phase III trials for complex perianal fistulas in Crohn's disease.

  • Ex J&J VP joins board of Immune Ex J&J VP joins board of Immune

    Immune will benefit from Durrant's knowledged of the iundstry gained during time in roles such as worldwide VP at Johnson &Johnson and VP, Pharmacia until its acquisition by Pfizer. ... Its lead product candidate is bertilimumab, which is in clinical

  • Former Novartis president joins Qu Biologics Former Novartis president joins Qu Biologics

    His senior industry experience will support Qu Biologics' plans to advance the development of its investigational immunotherapies for treatments such as Crohn's disease. ... Bob Pelzer's wealth of leadership experience with Novartis and DuPont will be

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 4 fully matching, plus 10 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics